Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in
patients with relapsing MS that had not responded optimally to standard immunomodulatory …

Background Rituximab, an anti-CD20 monoclonal antibody that depletes CD20+ B cells, has
demonstrated efficacy in peripheral neurological diseases. Whether this efficacy can be …

Background The anti-CD20 monoclonal antibody rituximab effectively depletes B
lymphocytes and has been successfully used in the therapy of immune-mediated disorders …

Background B cells are implicated in the pathogenesis of multiple sclerosis. A beneficial
effect of B-cell depletion using rituximab has been shown, but the complete mechanism of …

Background Rituximab is a recombinant chimeric monoclonal antibody against CD20, a
molecule expressed on cells of the B-cell lineage. A phase 2 clinical trial recently provided …

Background There is increasing evidence that B lymphocytes are involved in the
pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a …

Background Rituximab, a monoclonal antibody against the B-cell-specific surface protein
CD20, is being evaluated for treatment of multiple sclerosis and neuromyelitis optica. Both …

Objective: B cells and the humoral immune system have been implicated in the
pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety …

Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has
demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis …

Background and Objectives Patients with multiple sclerosis (PwMS) receiving extended
dosing of rituximab (RTX) have exhibited no return of disease activity, which suggests that …